Encouraging findings in heavily pretreated patients in multiple solid tumor indications, including MSS colorectal cancer , in ongoing Phase 1 Part 1b study evaluating NGM707, a dual ILT2/ILT4.
Jean-Frédéric Viret, Ph.D., has been appointed as Chief Financial Officer effective November 3, 2023 Continued to progress myeloid checkpoint solid tumor programs: NGM707, NGM831 and NGM438 .
NGM Bio Presents Preliminary Data from Phase 1 Monotherapy Dose Escalation Trial of NGM707 in Patients with Advanced or Metastatic Solid Tumors at 2022 ESMO-IO Annual Meeting streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Mirum Pharmaceuticals (NASDAQ:MIRM – Get Rating) and NextCure (NASDAQ:NXTC – Get Rating) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, analyst recommendations, dividends, earnings, institutional ownership and valuation. Profitability This table compares Mirum Pharmaceuticals and NextCure’s net margins, […]